1. Home
  2. ATXS vs NLOP Comparison

ATXS vs NLOP Comparison

Compare ATXS & NLOP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ATXS
  • NLOP
  • Stock Information
  • Founded
  • ATXS 2008
  • NLOP 2022
  • Country
  • ATXS United States
  • NLOP United States
  • Employees
  • ATXS N/A
  • NLOP N/A
  • Industry
  • ATXS Biotechnology: Pharmaceutical Preparations
  • NLOP
  • Sector
  • ATXS Health Care
  • NLOP
  • Exchange
  • ATXS Nasdaq
  • NLOP Nasdaq
  • Market Cap
  • ATXS 401.2M
  • NLOP 470.6M
  • IPO Year
  • ATXS 2015
  • NLOP N/A
  • Fundamental
  • Price
  • ATXS $6.81
  • NLOP $31.85
  • Analyst Decision
  • ATXS Strong Buy
  • NLOP Strong Buy
  • Analyst Count
  • ATXS 6
  • NLOP 1
  • Target Price
  • ATXS $25.67
  • NLOP $46.00
  • AVG Volume (30 Days)
  • ATXS 244.9K
  • NLOP 157.4K
  • Earning Date
  • ATXS 03-03-2025
  • NLOP 01-01-0001
  • Dividend Yield
  • ATXS N/A
  • NLOP 1.07%
  • EPS Growth
  • ATXS N/A
  • NLOP N/A
  • EPS
  • ATXS N/A
  • NLOP N/A
  • Revenue
  • ATXS N/A
  • NLOP $160,911,000.00
  • Revenue This Year
  • ATXS N/A
  • NLOP N/A
  • Revenue Next Year
  • ATXS N/A
  • NLOP N/A
  • P/E Ratio
  • ATXS N/A
  • NLOP N/A
  • Revenue Growth
  • ATXS N/A
  • NLOP N/A
  • 52 Week Low
  • ATXS $6.64
  • NLOP $22.16
  • 52 Week High
  • ATXS $16.90
  • NLOP $34.38
  • Technical
  • Relative Strength Index (RSI)
  • ATXS 31.94
  • NLOP 49.95
  • Support Level
  • ATXS $6.77
  • NLOP $30.69
  • Resistance Level
  • ATXS $7.30
  • NLOP $34.38
  • Average True Range (ATR)
  • ATXS 0.30
  • NLOP 0.85
  • MACD
  • ATXS 0.02
  • NLOP 0.06
  • Stochastic Oscillator
  • ATXS 14.66
  • NLOP 31.46

About ATXS Astria Therapeutics Inc.

Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.

About NLOP Net Lease Office Properties of Beneficial Interest

Net Lease Office Properties is a real estate investment trust. Through its subsidiaries it owns, operates, and finances office buildings. Its properties are primarily leased to corporate tenants on a single-tenant, net-lease basis. Its portfolio includes approximately 1.5 million square feet of Green-Certified Buildings, 4 LEED-Certified Buildings, and 1 BREEAM-Certified Building.

Share on Social Networks: